Hallum A V, Alberts D S, Lippman S M, Inclan L, Shamdas G J, Childers J M, Surwit E A, Modiano M, Hatch K D
Department of Obstetrics-Gynecology, University of Arizona, College of Medicine, Tucson 85724, USA.
Gynecol Oncol. 1995 Mar;56(3):382-6. doi: 10.1006/gyno.1995.1067.
The combination of 13-cis-retinoic acid (13-cRA) and interferon (IFN)-alpha 2a has been reported to be highly active in previously untreated squamous carcinoma of the cervix. In this phase II study, 13-cRA was given at a dose of 1 mg/kg/day and IFN-alpha 2a was given subcutaneously at a dose of 3 million units/m2/day. Thirteen of 14 patients enrolled in this study are evaluable for response and toxicity. There were no complete or partial responses. Ten patients had progressive disease and the remaining three had stable disease. Principle toxicities were fatigue, nausea, and vomiting. This regimen appears cross-resistant with radiotherapy and/or platinum-based cytotoxic therapy in heavily pretreated patients with squamous carcinoma of the cervix.
据报道，13-顺式维甲酸（13-cRA）与干扰素（IFN）-α 2a联合使用对先前未经治疗的宫颈鳞癌具有高度活性。在这项II期研究中，13-cRA的给药剂量为1mg/kg/天，IFN-α 2a皮下给药剂量为300万单位/m²/天。本研究纳入的14例患者中有13例可评估疗效和毒性。没有完全缓解或部分缓解的情况。10例患者病情进展，其余3例病情稳定。主要毒性为疲劳、恶心和呕吐。在先前接受过大量治疗的宫颈鳞癌患者中，该方案似乎与放疗和/或铂类细胞毒性疗法存在交叉耐药性。
